{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:35:34Z","timestamp":1793316934005,"version":"4.5.0"},"reference-count":34,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2024,1,16]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare cancer incidence, type, and survival between patients with idiopathic inflammatory myopathies (IIMs) in Western Australia (WA) and the general population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Administrative health data for hospitalized patients with incident IIM (n = 803, 56.5% female, median age 62.0 yrs), classified by a validated algorithm as polymyositis (PM; 36.2%), dermatomyositis (DM; 27.4%), inclusion body myositis (IBM; 17.1%), overlap myositis (OM; 10.7%), and other IIM (8.6%), were linked to WA cancer and death registries for the period of 1980 to 2014. Cancer incidence rates (CIRs) before and after IIM diagnosis as well as cancer mortality were compared with age-, sex-, and calendar year\u2013matched controls (n = 3225, 54.9% female, median age 64 yrs) by rate ratios (RRs) and Kaplan-Meier survival estimates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The prediagnosis CIR was similar for patients with IIM and controls (6.57 vs 5.95; RR 1.11, 95% CI 0.88-1.39) and for patients evolving to DM (n = 220) or other IIM subtypes (6.59 vs 6.56; RR 1.01, 95% CI 0.38-3.69). During follow-up, CIR was higher for all DM (4.05, 95% CI 3.04-5.29), with increased CIR for lung cancer vs controls (1.05 vs 0.33; RR 3.18, 95% CI 1.71-5.47). Cancer post diagnosis shortened life span by 59 months for patients with IIM (103 vs 162 months,<jats:italic>P<\/jats:italic>&lt; 0.01), but reduced survival rates were observed only in patients with DM and IBM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Cancer risk was not increased prior to IIM, but CIR for lung cancer was increased following DM diagnosis. As cancer reduced survival only in patients with DM and IBM, these data support a strategy of limited cancer screening in IIM.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2023-1044","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T13:25:33Z","timestamp":1706793933000},"page":"396-402","source":"Crossref","is-referenced-by-count":3,"title":["Cancer Risk and Mortality in Hospitalized Patients With Idiopathic Inflammatory Myopathies in Western Australia"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2833-7997","authenticated-orcid":false,"given":"Johannes C.","family":"Nossent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8469-2424","authenticated-orcid":false,"given":"Helen","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2982-2169","authenticated-orcid":false,"given":"David","family":"Preen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0535-963X","authenticated-orcid":false,"given":"Charles","family":"Inderjeeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"2024040105251558000_51.4.396.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468"},{"key":"2024040105251558000_51.4.396.2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.berh.2016.04.007","article-title":"Idiopathic inflammatory myositis","volume":"30","author":"Tieu","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2024040105251558000_51.4.396.3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.semarthrit.2019.04.002","article-title":"Immune-mediated necrotising myopathy: a critical review of current concepts","volume":"49","author":"Day","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2024040105251558000_51.4.396.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.101484"},{"key":"2024040105251558000_51.4.396.5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.rdc.2020.05.006","article-title":"Risk factors and cancer screening in myositis","volume":"46","author":"Moghadam-Kia","year":"2020","journal-title":"Rheum Dis Clin North Am"},{"key":"2024040105251558000_51.4.396.6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2024040105251558000_51.4.396.7","doi-asserted-by":"crossref","first-page":"e9639","DOI":"10.1097\/MD.0000000000009639","article-title":"Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts","volume":"97","author":"Leatham","year":"2018","journal-title":"Medicine"},{"key":"2024040105251558000_51.4.396.8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12016-015-8511-x","article-title":"Idiopathic inflammatory myopathies and malignancy: a comprehensive review","volume":"52","author":"Tiniakou","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2024040105251558000_51.4.396.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2489-y"},{"key":"2024040105251558000_51.4.396.10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-12-200106190-00008"},{"key":"2024040105251558000_51.4.396.11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13075-022-02963-y","article-title":"Long-term secular trends in dermatomyositis and polymyositis mortality in the USA from 1981 to 2020 according to underlying and multiple cause of death mortality data","volume":"25","author":"Qiao","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2024040105251558000_51.4.396.12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/acr.24786","article-title":"Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study","volume":"75","author":"Kronzer","year":"2023","journal-title":"Arthritis Care Res"},{"key":"2024040105251558000_51.4.396.13","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000635"},{"key":"2024040105251558000_51.4.396.14","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/acr.23010","article-title":"Validation of International Classification of Diseases codes for the epidemiologic study of dermatomyositis","volume":"69","author":"Kwa","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2024040105251558000_51.4.396.15","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/s41598-021-83729-5","article-title":"Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan","volume":"11","author":"Hsu","year":"2021","journal-title":"Sci Rep"},{"key":"2024040105251558000_51.4.396.16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/BOR.0000000000000327","article-title":"Epidemiology of sporadic inclusion body myositis","volume":"28","author":"Molberg","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"2024040105251558000_51.4.396.17","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/ene.12627","article-title":"High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study","volume":"22","author":"Dobloug","year":"2015","journal-title":"Eur J Neurol"},{"key":"2024040105251558000_51.4.396.18","doi-asserted-by":"crossref","first-page":"rkac102","DOI":"10.1093\/rap\/rkac102","article-title":"Validation of methods to identify people with idiopathic inflammatory myopathies using hospital episode statistics","volume":"6","author":"Hannah","year":"2022","journal-title":"Rheumatol Adv Pract"},{"key":"2024040105251558000_51.4.396.19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0738-081X(88)90044-2","article-title":"History and classification of polymyositis and dermatomyositis","volume":"6","author":"Bohan","year":"1988","journal-title":"Clin Dermatol"},{"key":"2024040105251558000_51.4.396.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-842X.2002.tb00682.x"},{"key":"2024040105251558000_51.4.396.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-842X.1999.tb01297.x"},{"key":"2024040105251558000_51.4.396.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03216.x"},{"key":"2024040105251558000_51.4.396.23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.semarthrit.2020.12.009","article-title":"Overall and site-specific cancer before and after diagnosis of idiopathic inflammatory myopathies: A nationwide study 2002-2016","volume":"51","author":"Dani","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2024040105251558000_51.4.396.24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00296-022-05214-0","article-title":"Long-term risks of malignancy in myositis-specific antibody-positive idiopathic inflammatory myopathy","volume":"43","author":"Izuka","year":"2023","journal-title":"Rheumatol Int"},{"key":"2024040105251558000_51.4.396.25","doi-asserted-by":"crossref","first-page":"e27230","DOI":"10.1097\/MD.0000000000027230","article-title":"Association between clinical phenotypes of dermatomyositis and polymyositis with myositis-specific antibodies and overlap systemic autoimmune diseases","volume":"100","author":"Chiang","year":"2021","journal-title":"Medicine"},{"key":"2024040105251558000_51.4.396.26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.21037\/atm-20-5215","article-title":"Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?","volume":"9","author":"Khanna","year":"2021","journal-title":"Ann Transl Med"},{"key":"2024040105251558000_51.4.396.27","doi-asserted-by":"crossref","first-page":"509354","DOI":"10.1155\/2013\/509354","article-title":"Clinical features of inflammatory myopathies and their association with malignancy: a systematic review in Asian population","volume":"2013","author":"Ungprasert","year":"2013","journal-title":"ISRN Rheumatol"},{"key":"2024040105251558000_51.4.396.28","doi-asserted-by":"crossref","first-page":"e0192491","DOI":"10.1371\/journal.pone.0192491","article-title":"Hospitalization mortality and associated risk factors in patients with polymyositis and dermatomyositis: a retrospective case-control study","volume":"13","author":"Wu","year":"2018","journal-title":"PLoS ONE"},{"key":"2024040105251558000_51.4.396.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211402"},{"key":"2024040105251558000_51.4.396.30","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00296-017-3799-x","article-title":"Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain","volume":"37","author":"Nu\u00f1o-Nu\u00f1o","year":"2017","journal-title":"Rheumatol Int"},{"key":"2024040105251558000_51.4.396.31","first-page":"438","article-title":"Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study","volume":"35","author":"Andr\u00e1s","year":"2008","journal-title":"J Rheumatol"},{"key":"2024040105251558000_51.4.396.32","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00296-019-04428-z","article-title":"Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study","volume":"39","author":"Motomura","year":"2019","journal-title":"Rheumatol Int"},{"key":"2024040105251558000_51.4.396.33","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatology"},{"key":"2024040105251558000_51.4.396.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2008.01.011"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2023-1044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T20:15:44Z","timestamp":1731183344000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2023-1044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,1]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.3899\/jrheum.2023-1044"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2023-1044","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}